Subscribe to RSS
DOI: 10.1055/a-1499-0119
SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia
Abstract
Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.
Publication History
Received: 22 April 2021
Accepted: 03 May 2021
Accepted Manuscript online:
04 May 2021
Article published online:
27 June 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 WHO. Strategic Advisory Group of Experts (SAGE) on immunization. Accessed May 10, 2021 at: https://www.who.int/immunization/sage/fr/
- 2 WHO. Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 . Accessed May 10, 2021
-
3
Johns Hopkins Coronavirus Disease Resource Center.
Accessed April 2021 at: https://coronavirus.jhu.edu
- 4 World Bank. Global Economic Prospects. Washington, DC: World Bank; 2020
- 5 Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021; 21 (02) e26-e35
- 6 Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020; 396 (10262): 1595-1606
- 7 Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol 2020; 20 (10) 581-582
-
8
MHRA.
Accessed May 10, 2021 at: https://yellowcard.mhra.gov.uk/
-
9 Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines). Accessed May 25, 2021 at: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf
- 10 Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci 2021; 25 (03) 1663-1669
- 11 Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021; 372 (699) n699
- 12 Scully M, Singh D, Lown R. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (23) 2202-2211
- 13 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
- 14 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2213
- 15 EMA. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Accessed May 10, 2021 at: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
- 16 Mahase E. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. BMJ 2021; 372 (774) n774
- 17 Merchant H. Can post immunisation increase in acute phase proteins explain the recent thrombotic events with CoViD vaccines?. BMJ 2021; 373: n883
- 18 NCIRD. Reports of cerebral venous sinus thrombosis with thrombocytopenia after Janssen COVID-19 vaccine. Accessed May 10, 2021 at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04/03-COVID-Shimabukuro-508.pdf
-
19
ANSM.
Accessed May 10, 2021 at: https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-davril-2021
-
20 India will review claims of AstraZeneca vaccine causing blood clots in ‘unusual’ sites. Accessed May 25, 2021 at: https://www.firstpost.com/health/india-will-review-claims-of-astrazeneca-vaccine-causing-blood-clots-in-unusual-sites-9527001.html
-
21
CDC.
Accessed May 10, 2021 at: https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
- 22 Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021; 384 (20) 1964-1965
- 23 Sadoff J, Davis K, Douoguih M. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer. N Engl J Med 2021; 384 (20) 1965-1966
- 24 Ferro JM, Aguiar de Sousa D. Cerebral venous thrombosis: an update. Curr Neurol Neurosci Rep 2019; 19 (10) 74
- 25 Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Büller HR, Rosendaal FR. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med 2007; 4 (09) e290
- 26 WHO. WHO Research Into Global Hazards of Travel (WRIGHT) Project: final report of phase I. Accessed May 10, 2021 at: https://www.who.int/cardiovascular_diseases/wright_project/phase1_report/WRIGHT%20REPORT.pdf
- 27 Jiménez D, García-Sanchez A, Rali P. et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 2021; 159 (03) 1182-1196
- 28 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4 (07) 1178-1191
- 29 Roubinian NH, Dusendang JR, Mark DG. et al. Incidence of 30-day venous thromboembolism in adults tested for SARS-CoV-2 infection in an integrated health care system in Northern California. JAMA Intern Med 2021; 181 (07) 997-1000
- 30 NCE. COVID-19 rapid guideline: managing the long-term effects of COVID-19 - NICE guideline [NG188]. Accessed May 10, 2021 at: https://www.nice.org.uk/GUIDANCE/ng188
- 31 Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?. Lancet 2021; 397 (10283): 1441-1443
- 32 Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. Nat Rev Neurol 2017; 13 (09) 555-565
- 33 Warkentin, et al. Spontaneous prothrombotic disorder ressembling to HIT. Am J Med 2008; 121: 632-636
- 34 Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15 (11) 2099-2114
- 35 Padmanabhan A, Jones CG, Pechauer SM. et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest 2017; 152 (03) 478-485
- 36 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; DOI: 10.1055/a-1481-3039.
- 37 McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2 (07) e437-e445
- 38 Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20 (06) 355-362
- 39 Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020; 136 (18) 2080-2089
- 40 ISTH. ISTH statement on AstraZeneca COVID-19 vaccine and thrombosis. Accessed May 10, 2021 at: https://www.isth.org/news/556057/ISTH-Statement-on-AstraZeneca-COVID-19-Vaccine-and-Thrombosis.htm
- 41 Hursting MJ, Pai PJ, McCracken JE. et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134 (05) 774-780
- 42 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
- 43 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
- 44 Siddiqi HK, Libby P, Ridker PM. COVID-19 - a vascular disease. Trends Cardiovasc Med 2021; 31 (01) 1-5
- 45 Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 384 (23) 2254-2256
- 46 Cuffe R. AstraZeneca vaccine: How do you weigh up the risks and benefits?. Accessed May 10, 2021 at: https://www.bbc.com/news/explainers-56665396
- 47 Sahu KK, Jindal V, Anderson J, Siddiqui AD, Jaiyesimi IA. Current perspectives on diagnostic assays and Anti-PF4 antibodies for the diagnosis of heparin-induced thrombocytopenia. J Blood Med 2020; 11: 267-277
- 48 EMA. European Medicines Agency Annex to Vaxzevria Art.5.3 - Visual risk contextualisation. Accessed May 10, 2021 at: https://www.ema.europa.eu/en/documents/chmp-annex/annex-vaxzevria-art53-visual-risk-contextualisation_en.pdf
- 49 Thrombosis Canada. Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). Accessed May 10, 2021 at: https://thrombosiscanada.ca/wp-uploads/uploads/2021/04/51.-Vaccine-induced-prothrobotic-immune-thrombcytopenia_02April2021.pdf
-
50 Guidance produced by the Expert Haematology Panel (EHP) focussed on Vaccine induced Thrombosis and Thrombocytopenia (VITT). Accessed May 25, 2021 at: https://b-s-h.org.uk/about-us/news/guidance-produced-by-the-expert-haematology-panel-ehp-focussed-on-vaccine-induced-thrombosis-and-thrombocytopenia-vitt/
-
51 https://www.conseil-national.medecin.fr/sites/default/files/external-package/bulletin/1v5iz4m/medecins_71.pdf
-
52 Responsibility of physicians in the vaccine decision. Accessed May 25, 2021 at: https://www.conseil-national.medecin.fr/publications/communiques-presse/responsabilite-medecins-decision-vaccinale
- 53 Nakajima Y, Mukai K, Takaoka K. et al. Establishing a new appropriate intramuscular injection site in the deltoid muscle. Hum Vaccin Immunother 2017; 13 (09) 2123-2129
- 54 Behrens RH, Patel V. Avoiding shoulder injury from intramuscular vaccines. Lancet 2021; 397 (10273): 471
- 55 Galea V, Khaterchi A, Robert F, Gerotziafas G, Hatmi M, Elalamy I. Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: confirmation in a prospective study. Platelets 2013; 24 (06) 441-447
- 56 Morel-Kopp MC, Mullier F, Gkalea V. et al; subcommittee on platelet immunology. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH. J Thromb Haemost 2016; 14 (12) 2548-2552
- 57 Tardy-Poncet B, Montmartin A, Piot M. et al; On Behalf Of The Gfht-Hit Study Group. Functional flow cytometric assay for reliable and convenient heparin-induced thrombocytopenia diagnosis in daily practice. Biomedicines 2021; 9 (04) 332
- 58 WHO. COVID-19 vaccines. Accessed May 10, 2021 at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines